Promising results led to an extension of LUMED into a phase I trial, where dose escalation and repeated administration in three patients was well tolerated, with comparable absorbed doses to the tumour lesions and moderate biochemical response (Ct, CEA) [27]. The gene discussed is CEACAM5; the disease is neoplasm.